Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Prediction: This Stock Could Double By 2031

Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?

Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Exelixis, Inc. $EXEL Shares Acquired by Merit Financial Group LLC

Here's Why Exelixis (EXEL) is a Strong Growth Stock

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib

Exelixis: Stable Demand And High Margins With Undervalued Shares

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

SG Americas Securities LLC Buys 15,203 Shares of Exelixis, Inc. $EXEL

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis: A Strong Contender in the Cancer Drug Market

Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of “Hold” from Analysts

Here's Why Exelixis (EXEL) is a Strong Value Stock

The Best Healthcare Stocks to Buy With $50 Right Now

Center For Asset Management LLC Purchases New Shares in Exelixis, Inc. $EXEL

Stock Market Today (LIVE): Nvidia Stock Up On GTC News, Markets Rally Despite Oil Hitting $101

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Exelixis, Inc. (EXEL) Presents at The Citizens Life Sciences Conference 2026 Transcript

CreativeOne Wealth LLC Raises Position in Exelixis, Inc. $EXEL

Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL

Exelixis, Inc. (EXEL) Presents at Leerink Global Healthcare Conference 2026 Transcript

Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL

Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL

Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of “Hold” by Analysts

Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Exelixis (NASDAQ:EXEL) Stock Price Down 9.4% After Analyst Downgrade

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade